Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20282050 | 1.00 | CA2 (0.51) | CA2CA5ASIRT2SIRT1SIRT3 | |
| SCHEMBL17484948 | 0.90 | SIRT2 (0.48) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19784346 | 0.90 | SIRT2 (0.50) | SIRT2SIRT1SIRT3MMP3MMP1 | |
| SCHEMBL19783968 | 0.89 | SIRT2 (0.53) | CA2CA5ASIRT2SIRT1SIRT3 | |
| SCHEMBL19784482 | 0.89 | SIRT2 (0.49) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL24276735 | 0.88 | SIRT2 (0.49) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL26153676 | 0.88 | CA1 (0.48) | CA2SIRT2SIRT1SIRT3MMP3 | |
| SCHEMBL31045343 | 0.88 | SIRT2 (0.56) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL29019197 | 0.87 | SIRT2 (0.44) | CA2SIRT2SIRT1SIRT3MMP3 | |
| SCHEMBL17211599 | 0.87 | SIRT2 (0.44) | CA2SIRT2SIRT1SIRT3MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-03-19 | — | — | US | disclosed |
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | CA2 1440/4885CA5A 2797/4885SIRT2 1659/4885 |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | CA2 1440/4885CA5A 2797/4885SIRT2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.